Download PDF
Open Access
CC BY-NC-ND 4.0 · Indian J Radiol Imaging
DOI: 10.1055/s-0045-1811599
Review Article

Ability of MRI Breast to Predict Pathologic Complete Response Following Neoadjuvant Systemic Therapy in Patients with Breast Cancer

Authors

  • Anu L. Joy

    1   Department of General Medicine, Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom

  • Teena Sleeba

    2   Department of Radiology, Rajagiri Hospital, Kochi, Kerala, India

  • Anu S. Easo 

    3   Department of Radiology, MOSC Medical College, Kolenchery, Kerala, India

  • Aju Mathew

    4   Department of Oncology, MOSC Medical College, Kolenchery, Kerala, India
Further Information
Also available at
  Permissions and Reprints
Preview

Abstract

Neoadjuvant systemic therapy (NST) has revolutionized the management of breast cancer by downstaging the disease and improving survival rates. Pathologic complete response, where surgical histopathological examination shows no invasive cancer in the breast and axilla, is not an uncommon scenario. In such patients, surgery may have added value to cancer control only for documenting the absence of cancer cells in the body in response to NST. In other words, could we have forfeited surgery for such patients if we were able to reliably identify them before surgery? However, the challenge lies in accurately identifying such patients. This narrative literature review explores the predictive ability of MRI scans in assessing pathological complete response (pCR) following NST. MRI demonstrates high sensitivity and specificity in detecting residual tumors post-NST, outperforming conventional imaging modalities. Combining diffusion-weighted MRI and contrast-enhanced MRI enhances diagnostic accuracy, particularly in monitoring response to chemotherapy. However, MRI's limitations include over- or underestimation of lesion size and morphology, necessitating complementary approaches for precise assessment. Vacuum-assisted core biopsy (VACB) emerges as a promising adjunct to MRI, offering high negative predictive value and minimal invasiveness. MRI-guided VACB enables accurate tissue sampling and lesion verification, augmenting diagnostic certainty. This integrated approach could particularly benefit patients with smaller-sized triple-negative or HER2-positive tumors. Further research is warranted to establish the clinical utility of combined MRI and VACB in predicting pCR post-NST and guiding personalized treatment decisions. Such advancements hold promise for a paradigm shift in breast cancer management, sparing patients from avoidable surgeries and optimizing therapeutic outcomes.

Keywords

pathologic complete response - neoadjuvant systemic therapy - diffusion-weighted MRI - contrast-enhanced MRI - breast MRI


Publication History

Article published online:
08 September 2025

© 2025. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India